97 related articles for article (PubMed ID: 24813764)
1. Relapsed/refractory diffuse large B-cell lymphoma: review of the management of transplant-eligible patients.
Lukenbill J; Hill B
Leuk Lymphoma; 2015 Feb; 56(2):293-300. PubMed ID: 24813764
[TBL] [Abstract][Full Text] [Related]
2. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study.
Van Den Neste E; Schmitz N; Mounier N; Gill D; Linch D; Trneny M; Milpied N; Radford J; Ketterer N; Shpilberg O; Dührsen U; Ma D; Brière J; Thieblemont C; Salles G; Moskowitz CH; Glass B; Gisselbrecht C
Bone Marrow Transplant; 2016 Jan; 51(1):51-7. PubMed ID: 26367239
[TBL] [Abstract][Full Text] [Related]
3. Salvage radiotherapy for primary refractory and relapsed diffuse large B-Cell lymphoma.
Brooks ED; Fang P; Pinnix CC
Br J Radiol; 2021 Nov; 94(1127):20210360. PubMed ID: 34378402
[TBL] [Abstract][Full Text] [Related]
4. Salvage therapy for relapsed or refractory diffuse large B-cell lymphoma: impact of prior rituximab.
Sud R; Friedberg JW
Haematologica; 2008 Dec; 93(12):1776-80. PubMed ID: 19050068
[No Abstract] [Full Text] [Related]
5. Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy.
Farooq U; Maurer MJ; Thompson CA; Thanarajasingam G; Inwards DJ; Micallef I; Macon W; Syrbu S; Lin T; Lin Y; Ansell SM; Nowakowski GS; Habermann TM; Cerhan JR; Link BK
Br J Haematol; 2017 Oct; 179(1):50-60. PubMed ID: 28653407
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma after second-line salvage chemotherapy: A retrospective study.
Yagi Y; Kanemasa Y; Sasaki Y; Sei M; Matsuo T; Ishimine K; Hayashi Y; Mino M; Ohigashi A; Morita Y; Tamura T; Nakamura S; Okuya T; Shimizuguchi T; Shingai N; Toya T; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Doki N; Okuyama Y; Shimoyama T
Cancer Med; 2023 Sep; 12(17):17808-17821. PubMed ID: 37635630
[TBL] [Abstract][Full Text] [Related]
7. [Role and progress of allogeneic hematopoietic stem cell transplantation in the treatment of refractory/relapsed diffuse large B-cell lymphoma].
Cao LQ; Mo XD
Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):308-312. PubMed ID: 38716606
[TBL] [Abstract][Full Text] [Related]
8. Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell Lymphoma.
Hilton LK; Ngu HS; Collinge B; Dreval K; Ben-Neriah S; Rushton CK; Wong JCH; Cruz M; Roth A; Boyle M; Meissner B; Slack GW; Farinha P; Craig JW; Gerrie AS; Freeman CL; Villa D; Rodrigo JA; Song K; Crump M; Shepherd L; Hay AE; Kuruvilla J; Savage KJ; Kridel R; Karsan A; Marra MA; Sehn LH; Steidl C; Morin RD; Scott DW
J Clin Oncol; 2023 Sep; 41(25):4164-4177. PubMed ID: 37319384
[TBL] [Abstract][Full Text] [Related]
9. The use of tafasitamab in diffuse large B-cell lymphoma.
Düll J; Topp M; Salles G
Ther Adv Hematol; 2021; 12():20406207211027458. PubMed ID: 34285786
[TBL] [Abstract][Full Text] [Related]
10. Challenges in Administering Salvage Therapy and Outcomes of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A LMIC Real-World Study.
Singh C; Jandial A; Jain A; Lad D; Khadwal A; Basher R; Bal A; Malhotra P; Prakash G
Indian J Hematol Blood Transfus; 2024 Apr; 40(2):231-236. PubMed ID: 38708153
[TBL] [Abstract][Full Text] [Related]
11. Relapsed/Refractory Primary Mediastinal B-cell Lymphoma: Where do we Stand?
Gulati N; Giulino-Roth L
Transplant Cell Ther; 2023 Nov; 29(11):649-650. PubMed ID: 37914501
[No Abstract] [Full Text] [Related]
12. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Tilly H; Gomes da Silva M; Vitolo U; Jack A; Meignan M; Lopez-Guillermo A; Walewski J; André M; Johnson PW; Pfreundschuh M; Ladetto M;
Ann Oncol; 2015 Sep; 26 Suppl 5():v116-25. PubMed ID: 26314773
[No Abstract] [Full Text] [Related]
13. Transplant without salvage: cut out the middleman.
Law AD; Mattsson JI
Lancet Haematol; 2024 May; 11(5):e310-e311. PubMed ID: 38583456
[No Abstract] [Full Text] [Related]
14. Refractory Burkitt Lymphoma: Diagnosis and Interventional Strategies.
Malfona F; Testi AM; Chiaretti S; Moleti ML
Blood Lymphat Cancer; 2024; 14():1-15. PubMed ID: 38510818
[TBL] [Abstract][Full Text] [Related]
15. Management of Relapsed Diffuse Large B-cell Lymphoma.
Crump M
Hematol Oncol Clin North Am; 2016 Dec; 30(6):1195-1213. PubMed ID: 27888875
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era.
Vardhana SA; Sauter CS; Matasar MJ; Zelenetz AD; Galasso N; Woo KM; Zhang Z; Moskowitz CH
Br J Haematol; 2017 Feb; 176(4):591-599. PubMed ID: 27982423
[TBL] [Abstract][Full Text] [Related]
17. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
Camicia R; Winkler HC; Hassa PO
Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness analysis of different salvage therapy intensities used for diffuse large B-cell lymphoma in Northern or Southern Alberta: an instrumental variable analysis.
Oh DH; Ghosh S; Chua N; Kostaras X; Tilley D; Chu M; Owen CJ; Stewart DA
Leuk Lymphoma; 2015 Jun; 56(6):1756-62. PubMed ID: 25284495
[TBL] [Abstract][Full Text] [Related]
19. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.
Crump M; Neelapu SS; Farooq U; Van Den Neste E; Kuruvilla J; Westin J; Link BK; Hay A; Cerhan JR; Zhu L; Boussetta S; Feng L; Maurer MJ; Navale L; Wiezorek J; Go WY; Gisselbrecht C
Blood; 2017 Oct; 130(16):1800-1808. PubMed ID: 28774879
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
